News

Opportunistic pathogens — microorganisms that live in us all,  but under specific circumstances can cause diseases like pneumonia — are more abundant in the mouths of people with Parkinson’s disease than healthy individuals, a study reported. This finding suggests that changes in oral bacteria in patients are related to disease…

Six microRNAs may serve as biomarkers of Parkinson’s disease progression and early diagnosis, a recent study suggests. That study, “Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease,” was published in the journal Translational Neurodegeneration. MicroRNAs (miRNAs)…

NRG Therapeutics has been awarded a $500,000 grant by the Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support the development of its potential disease-modifying therapy for Parkinson’s. That funding will go toward investigating how small molecules, developed by NRG, inhibit the opening of mitochondrial pores, known…

It’s been a long, evolutionary road for The Michael J. Fox Foundation’s (MJFF) annual Tour de Fox fundraiser, which kicks off virtually this year on Aug. 28. The worldwide cycling event invites riders of all ages and abilities to put on helmets, check bike tire pressure, and take…

Head trauma causing a person to black out, and lead exposure — even through hobbies — may more than double a person’s risk of developing Parkinson’s disease, according to a study of people in the New England area. Having a close relative with this disease was also identified as…

A new psychedelic drug formulation called AKO004 is now under development by Akome Biotech, a wholly owned subsidiary of Core One Labs, as a potential treatment for Parkinson’s disease. The company has filed a provisional patent application for AKO004 with the U.S. Patent and Trademark Office. The AKO004…

Adhera Therapeutics will develop MLR-1019 (armesocarb), a treatment candidate for easing Parkinson’s disease symptoms, following a licensing agreement with Melior Pharmaceuticals II. The therapy is the only one in development that’s designed to treat both Parkinson’s motor and non-motor symptoms simultaneously. “MLR-1019 represents what could be…

People with Parkinson’s disease who combine standard medication with various types of acupuncture treatments may see improvements in their motor function and quality of life, a review study from China suggests. However, its researchers noted that additional clinical trials are necessary to validate these findings. The study, “Acupuncture-Related…

The mesencephalic locomotor region, a brain region previously thought to control only walking and other forms of locomotion in vertebrates, also regulates postural changes and other movements, according to a study in mice. “It was surprising that within this region, which everybody has linked to locomotion, many of the neurons…

Inhibikase Therapeutics has received clearance from the U.S. Food and Drug Administration (FDA) to start a Phase 1 clinical trial evaluating its investigational, once-daily, oral medicine IkT-148009 in patients with Parkinson’s disease. The clearance comes after the agency reviewed the safety, tolerability and pharmacokinetic data from a Phase 1 study…